{"id":"epoetin-biosimilar","safety":{"commonSideEffects":[{"rate":"14.8%","effect":"Headache"},{"rate":"12.5%","effect":"Fatigue"},{"rate":"10.3%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2109092","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epoetin biosimilars mimic the action of endogenous erythropoietin, stimulating the production of red blood cells.","oneSentence":"Stimulates erythropoiesis by binding to the erythropoietin receptor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:27.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with chemotherapy"}]},"trialDetails":[{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT06764511","phase":"","title":"Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-08-30","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":60},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT02140736","phase":"","title":"Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2009-09","conditions":"Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies","enrollment":2333},{"nctId":"NCT02708914","phase":"PHASE3","title":"Study to Compare the Safety and Efficacy of UB-851 and Eprex®","status":"COMPLETED","sponsor":"UBI Pharma Inc.","startDate":"2016-03","conditions":"Renal Anemia","enrollment":269},{"nctId":"NCT02947438","phase":"PHASE3","title":"Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)","status":"COMPLETED","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2015-12","conditions":"Renal Anemia","enrollment":207},{"nctId":"NCT02522975","phase":"PHASE4","title":"Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)","status":"TERMINATED","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2015-08","conditions":"Renal Anaemia","enrollment":16},{"nctId":"NCT01626547","phase":"","title":"Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2010-12","conditions":"Chemotherapy-induced Symptomatic Anaemia, Solid Tumours, Malignant Lymphomas","enrollment":291},{"nctId":"NCT01184495","phase":"PHASE3","title":"Efficacy Study of Two Formulations of Erythropoietin","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2008-04","conditions":"Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis","enrollment":74},{"nctId":"NCT01121237","phase":"","title":"MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5","status":"COMPLETED","sponsor":"Sandoz","startDate":"2010-02","conditions":"Chronic Kidney Disease, End-stage Renal Disease, Anaemia","enrollment":2086},{"nctId":"NCT02191150","phase":"","title":"Study of Haemodialysis Patients Switching From Aranesp to Biosimilar","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06","conditions":"Anaemia","enrollment":272},{"nctId":"NCT02341547","phase":"","title":"Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'","status":"UNKNOWN","sponsor":"Penang Hospital, Malaysia","startDate":"2015-02","conditions":"End Stage Renal Failure, Anaemia","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":172,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Epoetin biosimilar","genericName":"Epoetin biosimilar","companyName":"Hospira, now a wholly owned subsidiary of Pfizer","companyId":"hospira-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stimulates erythropoiesis by binding to the erythropoietin receptor Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}